Antineoplastic drugs inducing cardiac and vascular toxicity – An update
Vascular Pharmacology · 2023-12 · 153 · 107223
DOI: 10.1016/j.vph.2023.107223 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Vascular Pharmacology, 2023-12. Verfasst von Serena Barachini und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Medicine, Laboratory for Cell Therapy, University of Pisa, Pisa, Italy. Hauptthemen laut MEDLINE: Antineoplastic Agents, Heart Diseases, Heart Failure, Neoplasms. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 86 Literaturangaben.
Abstract (Originalsprache)
With the improvement in cancer prognosis due to advances in antitumor therapeutic protocols and new targeted and immunotherapies, we are witnessing a growing increase in survival, however, at the same timeincrease in morbidity among cancer survivors as a consequences of the increased cardiovascular adverse effects of antineoplastic drugs. Common cardiovascular complications of antineoplastic therapies may include cardiac complications such as arrhythmias, myocardial ischemia, left ventricular dysfunction culminating in heart failure as well as vascular complications including arterial hypertension, thromboembolic events, and accelerated atherosclerosis. The toxicity results from the fact that these drugs not only target cancer cells but also affect normal cells within the cardiovascular system. In this article, we review the clinical features and main mechanisms implicated in antineoplastic drug-induced cardiovascular toxicity, including oxidative stress, inflammation, immunothrombosis and growth factors-induced signaling pathways.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical and Experimental Medicine, Laboratory for Cell Therapy, University of Pisa, Pisa, Italy.
- Department of Pathology, Laboratory of Biochemistry, University of Pisa, Pisa, Italy.
- Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary; HCEMM-SU Cardiometabolic Immunology Research Group, Budapest, Hungary; MTA-SE Momentum Cardio-Oncology and Cardioimmunology Resea…
- Medical Physiology Department, Center of Excellence for Research in Regenerative Medicine and Applications (CERRMA), Faculty of Medicine, Alexandria University, Egypt.
- Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
- Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary; Pharmahungary Group, Szeged, Hungary.
Zitieren
APA
Barachini, S., Ghelardoni, S., Varga, Z. V., Mehanna, R. A., Montt-Guevara, M. M., Ferdinandy, P., & Madonna, R. (2023). Antineoplastic drugs inducing cardiac and vascular toxicity – An update. Vascular Pharmacology, 153, 107223. https://doi.org/10.1016/j.vph.2023.107223
Vancouver
Barachini S, Ghelardoni S, Varga ZV, Mehanna RA, Montt-Guevara MM, Ferdinandy P, et al. Antineoplastic drugs inducing cardiac and vascular toxicity – An update. Vascular Pharmacology. 2023;153:107223. doi:10.1016/j.vph.2023.107223
BibTeX
@article{Barachini2023,
author = {Barachini, Serena and Ghelardoni, Sandra and Varga, Zoltán V and Mehanna, Radwa A and Montt-Guevara, Maria Magdalena and Ferdinandy, Péter and Madonna, Rosalinda},
title = {Antineoplastic drugs inducing cardiac and vascular toxicity – An update},
journal = {Vascular Pharmacology},
year = {2023},
volume = {153},
pages = {107223},
doi = {10.1016/j.vph.2023.107223}
}
EUVIMED